DRAK2 anticorps (C-Term)
Aperçu rapide pour DRAK2 anticorps (C-Term) (ABIN954980)
Antigène
Voir toutes DRAK2 (STK17B) AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 319-348, C-Term
-
Specificité
- This antibody reacts to STK17B.
-
Réactivité croisée (Details)
- Species reactivity (tested):Human.
-
Purification
- Affinity chromatography on Protein A
-
Immunogène
- KLH conjugated synthetic peptide between 319-348 amino acids from the C-terminal region of human STK17B
-
Isotype
- Ig Fraction
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS, 0.09 % (W/V) sodium azide
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- Avoid repeated freezing and thawing.
-
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- DRAK2 (STK17B) (serine/threonine Kinase 17b (STK17B))
-
Autre désignation
- STK17B / DRAK2
-
Sujet
- Synonyms: DAP kinase-related apoptosis-inducing protein kinase 2, Serine/threonine-protein kinase 17B
-
Poids moléculaire
- 42344 Da
-
ID gène
- 9262
-
NCBI Accession
- NP_004217
Antigène
-